Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AtriCure, Inc. stock logo
ATRC
AtriCure
$34.13
+2.3%
$37.61
$18.94
$43.11
$1.67B1.53671,779 shs467,008 shs
Paragon 28, Inc. stock logo
FNA
Paragon 28
$13.08
+0.2%
$12.93
$4.65
$13.13
$1.10B1.54893,741 shs390,381 shs
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$86.62
+1.7%
$92.25
$62.39
$109.58
$1.95B0.89154,145 shs198,464 shs
NovoCure Limited stock logo
NVCR
NovoCure
$17.94
+2.4%
$21.19
$11.70
$34.13
$1.97B0.631.19 million shs588,205 shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AtriCure, Inc. stock logo
ATRC
AtriCure
+2.31%+1.52%-12.40%+12.27%+25.43%
Paragon 28, Inc. stock logo
FNA
Paragon 28
+0.11%+0.50%+0.46%+22.01%+11.89%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
+1.71%+2.48%-6.01%-5.30%+35.28%
NovoCure Limited stock logo
NVCR
NovoCure
+2.40%-2.71%-2.55%-40.18%+24.67%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AtriCure, Inc. stock logo
ATRC
AtriCure
3.4057 of 5 stars
4.53.00.00.01.72.50.6
Paragon 28, Inc. stock logo
FNA
Paragon 28
1.448 of 5 stars
1.25.00.00.01.43.30.6
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
2.3379 of 5 stars
1.31.03.30.03.73.31.3
NovoCure Limited stock logo
NVCR
NovoCure
3.3153 of 5 stars
3.41.00.04.51.41.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AtriCure, Inc. stock logo
ATRC
AtriCure
3.00
Buy$49.4444.87% Upside
Paragon 28, Inc. stock logo
FNA
Paragon 28
2.33
Hold$14.208.56% Upside
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
2.67
Moderate Buy$95.259.96% Upside
NovoCure Limited stock logo
NVCR
NovoCure
2.80
Moderate Buy$35.8099.55% Upside

Current Analyst Ratings Breakdown

Latest LMAT, FNA, ATRC, and NVCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/28/2025
AtriCure, Inc. stock logo
ATRC
AtriCure
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$66.00 ➝ $52.00
3/27/2025
AtriCure, Inc. stock logo
ATRC
AtriCure
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/27/2025
AtriCure, Inc. stock logo
ATRC
AtriCure
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$51.00 ➝ $46.00
3/27/2025
AtriCure, Inc. stock logo
ATRC
AtriCure
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$51.00 ➝ $51.00
3/21/2025
AtriCure, Inc. stock logo
ATRC
AtriCure
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$51.00 ➝ $51.00
2/28/2025
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$105.00 ➝ $110.00
2/28/2025
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
2/28/2025
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
2/13/2025
AtriCure, Inc. stock logo
ATRC
AtriCure
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$36.00 ➝ $45.00
2/13/2025
AtriCure, Inc. stock logo
ATRC
AtriCure
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$40.00 ➝ $50.00
2/13/2025
AtriCure, Inc. stock logo
ATRC
AtriCure
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$36.00 ➝ $48.00
(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AtriCure, Inc. stock logo
ATRC
AtriCure
$465.31M3.59N/AN/A$9.46 per share3.61
Paragon 28, Inc. stock logo
FNA
Paragon 28
$256.18M4.29N/AN/A$2.05 per share6.38
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$219.86M8.89$1.53 per share56.52$13.38 per share6.47
NovoCure Limited stock logo
NVCR
NovoCure
$605.22M3.26N/AN/A$3.39 per share5.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AtriCure, Inc. stock logo
ATRC
AtriCure
-$44.70M-$0.95N/AN/AN/A-9.61%-6.80%-5.19%4/29/2025 (Estimated)
Paragon 28, Inc. stock logo
FNA
Paragon 28
-$57.53M-$0.63N/AN/AN/A-25.31%-37.90%-18.22%5/14/2025 (Estimated)
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$30.10M$1.9447.3339.922.2219.40%13.15%11.47%5/1/2025 (Estimated)
NovoCure Limited stock logo
NVCR
NovoCure
-$207.04M-$1.56N/AN/AN/A-25.93%-41.48%-12.74%4/24/2025 (Estimated)

Latest LMAT, FNA, ATRC, and NVCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025N/A
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$0.50N/AN/AN/A$57.61 millionN/A
4/24/2025N/A
NovoCure Limited stock logo
NVCR
NovoCure
-$0.47N/AN/AN/A$147.57 millionN/A
3/6/2025Q4 2024
Paragon 28, Inc. stock logo
FNA
Paragon 28
-$0.12-$0.13-$0.01-$0.13$70.81 million$71.75 million
2/27/2025Q4 2024
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$0.49$0.49N/A$0.49$55.99 million$55.81 million
2/27/2025Q4 2024
NovoCure Limited stock logo
NVCR
NovoCure
-$0.34-$0.61-$0.27-$0.61$161.30 million$161.27 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AtriCure, Inc. stock logo
ATRC
AtriCure
N/AN/AN/AN/AN/A
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/A
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$0.800.92%+13.30%41.24%14 Years
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A

Latest LMAT, FNA, ATRC, and NVCR Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/18/2025
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
quarterly$0.200.9%3/13/20253/13/20253/27/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AtriCure, Inc. stock logo
ATRC
AtriCure
0.13
3.65
2.62
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.79
3.50
1.60
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
N/A
7.74
5.52
NovoCure Limited stock logo
NVCR
NovoCure
0.27
1.49
1.44

Institutional Ownership

CompanyInstitutional Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
99.11%
Paragon 28, Inc. stock logo
FNA
Paragon 28
63.57%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
84.64%
NovoCure Limited stock logo
NVCR
NovoCure
84.61%

Insider Ownership

CompanyInsider Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
3.20%
Paragon 28, Inc. stock logo
FNA
Paragon 28
15.32%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
10.79%
NovoCure Limited stock logo
NVCR
NovoCure
6.29%
CompanyEmployeesShares OutstandingFree FloatOptionable
AtriCure, Inc. stock logo
ATRC
AtriCure
1,30048.88 million47.32 millionOptionable
Paragon 28, Inc. stock logo
FNA
Paragon 28
343,00083.94 million70.89 millionOptionable
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
49022.56 million20.06 millionOptionable
NovoCure Limited stock logo
NVCR
NovoCure
1,320109.92 million101.40 millionOptionable

Recent News About These Companies

Novocure to Report First Quarter 2025 Financial Results
NovoCure (NASDAQ:NVCR) Cut to Sell at StockNews.com
Wells Fargo Sticks to Its Buy Rating for NovoCure (NVCR)

New MarketBeat Followers Over Time

Media Sentiment Over Time

AtriCure stock logo

AtriCure NASDAQ:ATRC

$34.13 +0.77 (+2.31%)
Closing price 04/2/2025 04:00 PM Eastern
Extended Trading
$33.10 -1.03 (-3.02%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Paragon 28 stock logo

Paragon 28 NYSE:FNA

$13.08 +0.02 (+0.15%)
Closing price 04/2/2025 03:58 PM Eastern
Extended Trading
$13.04 -0.04 (-0.27%)
As of 04:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

LeMaitre Vascular stock logo

LeMaitre Vascular NASDAQ:LMAT

$86.62 +1.46 (+1.71%)
Closing price 04/2/2025 04:00 PM Eastern
Extended Trading
$74.60 -12.02 (-13.88%)
As of 05:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

NovoCure stock logo

NovoCure NASDAQ:NVCR

$17.94 +0.42 (+2.40%)
Closing price 04/2/2025 04:00 PM Eastern
Extended Trading
$18.73 +0.79 (+4.38%)
As of 04:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.